CES 2027 is shaping up to be a turning point for hearing technology. When the Consumer Technology Association announced that Digital Health would graduate from a show-floor category to a full conference track — complete with its own Health Stage — it sent a clear signal: hearing health is no longer a side conversation. It is now part of the main event.

For those of us who follow the hearing industry closely, this shift is worth pausing on. The days when hearing aids were tucked away in a quiet corner of the audio hall are ending. They are becoming a core part of the digital health story. And JINGHAO Medical is proud to be part of that story, exhibiting at CES 2027 at the Venetian Expo, Halls A-D, Booth 54635, with a full lineup of CES hearing aids.

CES 2027 · Las Vegas · January 6-9 · JINGHAO MEDICAL exhibiting at Venetian Expo, Booth 54635

CES Hearing Aids: What to Expect at CES 2027

CES hearing aids are no longer a niche category. They are becoming one of the most dynamic segments of the digital health ecosystem. At CES 2027, the focus will be on three major shifts: on-device AI moving from feature to foundation, OTC hearing aids delivering clinical-grade performance, and manufacturing capability becoming the quiet differentiator for global brands.

JINGHAO Medical is at the center of this shift, bringing its latest CES hearing aids to Booth 54635. These devices combine 16-channel processing, 3D spatial hearing, adaptive feedback suppression, and IP68 waterproofing — all built on a foundation of FDA 510(k) clearance, CE-MDR certification, and ISO 13485 quality systems.

AI Moves from Feature to Foundation

The most important trend heading into CES 2027 is the quiet revolution happening inside the device itself. On-device AI is no longer a marketing bullet point. It is becoming the baseline for CES hearing aids.

Edge computing means lower latency, better privacy, and the ability to adapt to acoustic environments without relying on a smartphone. For enterprise buyers, this is more than a technical detail. Devices with genuine on-device AI are simply more reliable across the messy, unpredictable environments where people actually live and work.

At the heart of JINGHAO’s AI-powered hearing aids is the A16 chipset platform, which delivers:

• 17dB Premium AI Noise Cancellation: Ensures sharp, crystal-clear speech focus during multi-person social gatherings or outdoor rush hours.
• Multi-Scene Adaptability: Pre-loaded with 6 optimized listening profiles, fully integrating automatic Speech Enhancer, active Wind Noise Management, and a professional-grade Music Program.
• 4th Gen Feedback Management: Armed with a lightning-fast anti-whistling algorithm that neutralizes piercing feedback in milliseconds, drastically enhancing initial fitting satisfaction and long-term user compliance.

JINGHAO A16 chipset platform — Advanced Algorithm Matrix for complex acoustic environments

The OTC Market: Growth Meets Infrastructure Gap

The OTC hearing aid market was valued at roughly USD 1.05 billion in 2026 and is projected to reach USD 1.95 billion by 2036, growing at a CAGR of about 6.4%. North America leads, thanks to regulatory clarity and rising consumer awareness.

But growth is not the same as access. The FDA estimates that about 30 million American adults have some degree of hearing impairment, yet most remain untreated. The OTC category was designed to close that gap. The problem is that many OTC devices still lack the clinical-grade signal processing needed to perform consistently in real-world noise.

This is where the supply chain becomes the story. As the OTC category expands, FDA approved OTC hearing aids are becoming the entry point for millions of adults who previously went without help. But bringing these devices to market at scale requires more than a clearance letter. It requires manufacturing infrastructure, engineering depth, and quality systems that can support mass production without cutting corners.

Manufacturing as the Hidden Competitive Layer

CES showcases prototypes. The hearing industry runs on production lines.

For global brands, retail chains, and healthcare organizations that want to offer hearing solutions under their own labels, the barrier is rarely the product concept. It is manufacturing execution. Not every organization has the engineering resources or regulatory expertise to develop hearing aids from scratch. This is where hearing aid OEM partnerships become critical — connecting brand owners with established manufacturers who already hold the certifications, quality systems, and production capacity required for international distribution.

Vertically integrated manufacturers occupy a distinct position here. They control key stages of production, from chipset integration to acoustic tuning and final assembly. That control translates into consistency — the ability to deliver the same performance across thousands of units.

A Case in Point: JINGHAO at CES 2027

One manufacturer demonstrating this model at CES 2027 is JINGHAO Hearing Aids (Huizhou Jinghao Medical Technology Co., Ltd.), the sole listed hearing aid manufacturer in China, exhibiting at the Venetian Expo, Halls A-D, Booth 54635. Its CES hearing aids are built to meet the demands of global distributors and clinical partners.

The company runs a 29,213 square meter semi-automated facility under ISO 13485 quality management systems and holds FDA 510(k) clearance and EU CE MDR certification. Its product portfolio includes 16-channel processing, 3D spatial hearing, adaptive feedback suppression, and IP68 waterproofing — technologies that line up directly with the trends being showcased at CES 2027.

JINGHAO hearing-aid manufacturing park — 29,213 sqm semi-automated facility under ISO 13485

For international distributors and procurement teams, meeting manufacturers like JINGHAO at CES offers something a catalog cannot: the chance to evaluate regulatory documentation, production capacity, and engineering capability in person.

JINGHAO Medical CES 2027 exhibitor listing — Venetian Expo, Booth 54635

What to Watch for at CES 2027

Three themes will define the hearing health conversation at CES 2027:

• On-device AI as the baseline expectation: Not a premium feature, but a fundamental requirement for reliable performance in real-world environments.
• OTC category expansion with clinical-grade performance: The winners will be those who can deliver clinical-grade performance at consumer-friendly prices.
• Manufacturing capability as the quiet differentiator: The factor that determines which brands can actually scale from prototype to mass production.

Hearing health is no longer a standalone category. It is part of the broader digital health ecosystem, and CES 2027 will make that clear.

Frequently Asked Questions